Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 327 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Malignant Central Nervous System Neoplasm Clear all
Completed Phase 1 Interventional

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

NCT00303940
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, talabostat mesylate, temozolomide, pharmacological study
Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 4, 2026, 10:43 PM EDT
Not listed Phase 2 Interventional

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

NCT00114309
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
Interventions
131-I-TM-601, 131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

NCT02595905
View directory record Official record
Conditions
Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
798
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Results available

Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors

NCT00308165
View directory record Official record
Conditions
Brain Neoplasms, Primary Malignant
Interventions
Convection-Enhanced Delivery, Topotecan
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
1 Year and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 4, 2026, 10:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

NCT01110876
View directory record Official record
Conditions
Brain Cancer, Glioblastoma Multiforme
Interventions
Vorinostat, Erlotinib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 4, 2026, 10:43 PM EDT
Recruiting Phase 1 Interventional

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

NCT04732065
View directory record Official record
Conditions
Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm, Spinal Cord Glioma, World Health Organization (WHO) Grade III Glioma, CNS Tumor, Central Nervous System Tumor
Interventions
ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
Drug · Radiation · Procedure
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years to 21 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NCT00589784
View directory record Official record
Conditions
CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions
Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Lerapolturev in Recurrent Malignant Glioma

NCT02986178
View directory record Official record
Conditions
Malignant Glioma
Interventions
lerapolturev, Lomustine
Biological · Drug
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 4, 2026, 10:43 PM EDT
Completed No phase listed Observational

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

NCT00002485
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
26
States / cities
Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

NCT00101270
View directory record Official record
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

NCT00038441
View directory record Official record
Conditions
Glioma, Brain Neoplasms
Interventions
DTI-015
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme

NCT00890032
View directory record Official record
Conditions
Recurrent Central Nervous System Neoplasm
Interventions
BTSC mRNA-loaded DCs
Biological
Lead sponsor
John Sampson
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

NCT00638898
View directory record Official record
Conditions
Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

NCT00387933
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
hydroxyurea, imatinib mesylate, vatalanib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

NCT00008008
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, sargramostim, cyclophosphamide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
2
States / cities
Paterson, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 3 Interventional

High Light and Low Light Dose PDT in Glioma

NCT00118222
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
porfimer sodium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional

Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00005859
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
tipifarnib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas

NCT00004041
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Ad5CMV-p53 gene, conventional surgery
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

NCT00363272
View directory record Official record
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ispinesib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

NCT00006102
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
becatecarin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
198
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

NCT02415153
View directory record Official record
Conditions
Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Primary Central Nervous System Neoplasm, Refractory Primary Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 20 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

NCT00613132
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Gleevec, RAD001, and Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

NCT01682746
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin (porfimer sodium) & photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
6 Months to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 4, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

NCT00070096
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 4, 2026, 10:43 PM EDT